Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.
- 1 January 1984
- journal article
- Vol. 27 (1), 115-7
Abstract
The pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 has been studied in 6 healthy male volunteers following a single intravenous dose of 2.5 mg. The drug was only slightly bound to plasma proteins (40 +/- 8%, mean +/- SD). A negligible amount (less than 0.2% of the dose) of unchanged drug was recovered in urine. Hepatic elimination was rapid, as shown by a short t1/2 of 0.9 +/- 0.2 h, and high total plasma and blood clearances of 691 +/- 216 ml/min and 716 +/- 199 ml/min, respectively. The fast decline of plasma levels from about 60 to 2 ng/ml accounts for the short-lasting reversal of benzodiazepine-induced sedation by Ro 15-1788.This publication has 9 references indexed in Scilit:
- Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788Psychopharmacology, 1983
- Effect of the benzodiazepine antagonist Ro 15‐1788 on flunitrazepam‐ induced sleep changes.British Journal of Clinical Pharmacology, 1983
- Determination of the benzodiazepine antagonist Ro 15-1788 in plasma by high-performance liquid chromatography with UV detection.1983
- Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788European Journal of Clinical Pharmacology, 1983
- Determination of Ro 15-1788, a Benzodiazepine Antagonist, in Human Plasma by Gas-Liquid Chromatography with Nitrogen-Phosphorus DetectionPharmacology, 1983
- RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.British Journal of Clinical Pharmacology, 1982
- INVESTIGATION IN MAN OF THE EFFICACY OF A BENZODIAZEPINE ANTAGONIST, Ro 15-1788The Lancet, 1981
- Selective antagonists of benzodiazepinesNature, 1981